pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Vyndamax · news · pharmadog
← back to Vyndamax
News mentioning Vyndamax
14
stories
14d
BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations
biospace
21d
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
biopharma dive
22d
Pfizer expands multibillion-dollar cost-cutting plan
biopharma dive
24d
5 companies advancing ATTR assets in the wake of Wainua’s fail
biospace
27d
Alnylam plunges as earnings deliver ‘one-two punch’
biopharma dive
29d
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
Jul 22, 26
Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug
fiercebiotech
Jul 9, 26
AstraZeneca, Ionis drug fails big heart disease study in major setback
biopharma dive
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Apr 29, 26
STAT+: Pharmalittle: We’re reading about the FDA speeding up trials, a Supreme Court hearing on ‘skinny labels,’ and more
stat
Apr 28, 26
Pfizer delays patent cliff for blockbuster Vyndamax
endpoints
Apr 28, 26
Pfizer deals extend patent life for a top-selling rare disease drug
biopharma dive
Apr 28, 26
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
biopharma dive
Apr 27, 26
STAT+: Astellas retries XLMTM gene therapy after deaths
stat
